A nanoparticle-mediated cytotoxic drug can selectively be delivered to cancer cells via exotoxin A to activate NLRP3, cleave GSDMD, and mediate pyroptosis at the primary tumor site [72]. Here, NLRP3 is linked to neoplasm.